Armata Pharmaceuticals Inc.

15/11/2024 | Press release | Distributed by Public on 15/11/2024 20:06

Management Change/Compensation Form 8 K

Item 1.01 Entry into a Material Definitive Agreement.

On November 12, 2024, the Company entered into amendments to (i) that certain credit and security agreement (as amended, the "Credit Agreement"), dated as of July 10, 2023, by and among the Company, as borrower, Innoviva Strategic Opportunities LLC ("Innoviva"), as lender, and certain domestic subsidiaries of the Company, as guarantors (the "Second Amendment to Credit Agreement") and (ii) that certain convertible credit and security agreement (as amended, the "Convertible Credit Agreement"), dated as of January 10, 2023, by and among the Company, as borrower, Innoviva, as lender, and certain domestic subsidiaries of the Company, as guarantors (the "Third Amendment to Convertible Credit Agreement" and together with the Second Amendment to Credit Agreement, the "Amendments"). Pursuant to the Amendments, the parties agreed to extend the maturity dates of the Credit Agreement and Convertible Credit Agreement to January 10, 2026.

The foregoing descriptions of the Second Amendment to Credit Agreement and the Third Amendment to Convertible Credit Agreement are qualified in their entirety by the full text of such documents, which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, and are incorporated herein by reference.